Enalapril/nitrendipine

Drug Profile

Enalapril/nitrendipine

Alternative Names: Eneas; Nitrendipine/enalapril

Latest Information Update: 15 Jul 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vita
  • Class Antihypertensives; Dihydropyridines; Dipeptides; Small molecules
  • Mechanism of Action ACE inhibitors; Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Essential hypertension

Most Recent Events

  • 01 Oct 2013 Warner Chilcott has been acquired and merged into Actavis Inc
  • 30 Oct 2009 Warner Chilcott has acquired the global pharmaceutical business of Procter & Gamble
  • 28 Jul 2005 Fournier-Pharma has been acquired by Solvay
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top